| Wissenschaftl. Titel | A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants with Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation |
| Erkrankung |
Verdauung:
Gallengangs-/Gallenblasenkrebs (maligne biliäre Tumoren):
Erstlinie
|
| Molekularer Marker |
IDH1 |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 09.04.2025 Admin02
geändert 27.06.2025 Admin07